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The eukaryotic translation initiation factor eIF3a is one of the core subunits of the translation initiation complex eIF3, responsible
for ribosomal subunit joining and mRNA recruitment to the ribosome. It is known to play an important role in general translation
initiation as well as in the speciﬁc translational regulation of various gene products, among which many inﬂuence tumour
development,progression,andthetherapeuticallyimportantpathwaysofDNAdamagerepair.Therefore,beyonditsroleinprotein
synthesis, eIF3a is emerging as regulator in tumour pathogenesis and therapy response and, therefore, a potential tumor marker.
Bymeansofatissuemicroarray(TMA)forhistopathologicalandstatisticalassessment,wehereshoweIF3aexpressionin103cases
of squamous cell carcinoma of the oral cavity (OSCC), representing tissues from 103 independent patients. A subset of the study
cohort was treated with platinum based therapy. Our results show that the 170kDa protein is upregulated in OSCC and correlates
with good overall survival. Overexpressing tumors respond better to platinum-based chemotherapy, suggesting eIF3a as a putative
predictive as well as prognostic tumor marker in OSCC.
1.Introduction
Head and neck squamous cell carcinomas (SCCs) range at
place six of the most common cancers worldwide. They
are responsible for approximately 650,000 newly diagnosed
tumors and an annual rate of 350,000 deaths [1]. Cancers
of the oral cavity are a large subgroup (48%) of head and
neck tumors, where more than 90% are SCCs [2]. The major
risk factors for oral cancer development are smoking or
chewing tobacco as well as alcohol abuse. In Asian countries,
betel nut and gutkha quid consumption is responsible for
exceptional high cancer prevalence [2]. Even if being inde-
pendent risk factors, alcohol and tobacco show synergistic
eﬀects in increasing the risk of cancer development when
used together. This is partially due to the fact that the
consumptionofalcoholincreasesthepermeabilityoftheoral
mucosa which enables an enhanced eﬀect of carcinogenic
nitrosamines and polycyclic hydrogen contained in tobacco.
Other risk factors are insuﬃcient oral hygiene, chronic
pressurebydentalprostheses,andchronicdiseases,including
infection with human papilloma virus [3–5]. First diagnosis
oforalsquamouscellcarcinomas(OSCC)isfrequentlyatlate
disease stage, with two thirds of patients baring a tumor of
stage III or IV. These tumors, therefore, go along with severe
morbidity and a long-term survival lower than 50%, despite
advances in surgery and conservative cancer treatments
(radiotherapy, chemotherapy and immunotherapy) of oral
cancer [6]. A need for new prognostic and predictive
biomarkers is given and their investigation is regarded as
essential to improve OSCC management.
Current OSCC treatment is a single modality ther-
apy for early stage and multimodality therapeutic strategy2 Journal of Oncology
in cases of advanced tumors. A large number of early
detected tumors will be subjected to surgical excision,
as long-term sequelae associated with radiotherapy can
be circumvented. Patients with late stage tumors usually
have to undergo surgery in combination with preoperative
or postoperative radiation therapy [7] Approaches with
adjuvant chemotherapy are controversially discussed, with
yet no common guidelines. Chemotherapy regimens consist
of a combination of 5-ﬂuorouracil (5-FU) with platinum-
containing drugs, including cisplatin and carboplatin
[8].
eIF3a as Tumor Marker. The eukaryotic translation initi-
ation factor (eIF) 3a is a 170kDa protein and presents
the largest subunit of the eIF3 complex. eIF3 is involved
in the translation initiation process at the formation of
Met-tRNAi-40S preinitiation complex, and it regulates the
recruitment of mRNA to this complex (via an interaction
with eIF4G). eIF3 is responsible for the prevention of
immatureribosomalsubunitjoiningandscaﬀoldsnumerous
translation initiation interactions in this rate-limiting step
of protein synthesis [9]. eIF3a can be seen as key regulator
bringing together mRNA and the ribosome. As the eIF3
complex is an assembly of up to 13 proteins, it still remains
an open question which subunits determine the major
functions of eIF3. eIF3a together with eIF3b, eIF3c, eIF3e,
eIF3f, and eIF3h is known to form the functional core of
the eIF3 multisubunit complex [10]. Opposing this fact,
eIF3a was reported recently to be not essential for general
translation, as its knockdown reduced protein synthesis for
only 15–20% in vitro [11, 12]. In accordance with this
ﬁnding, eIF3a was reported to be responsible for the speciﬁc
translation of a set of proteins, of which p27, RRM2 and
tyrosinated α-tubulin have already been determined [11,
13]. eIF3a is known to be upregulated in various cancer
entities, ranging from breast, cervical, colon, esophageal to
lung, and gastric cancers [14–19]. Of particular importance
is the vast diﬀerence in results of the mentioned studies.
Dellas et al. ﬁrst described the overexpression of eIF3a to
correlate with a better prognosis in SCC, represented by
cervical neoplasias [18]. Another study conducted in SCC
focused on esophageal cancer, again showing a correlation
of high eIF3a expression with good clinical prognosis [16].
Similar to these studies, eIF3a expression was analysed in
adenocarcinomas (ACs) with rather contrasting outcomes.
In a previous study, we could show in colon cancer that
high eIF3a expression correlates with poor prognosis [19].
This discrepancy between AC and SCC is expected to be
originating from diﬀerent patterns of dediﬀerentiation and
recruitment of protein synthesis machinery in the diﬀerent
cancer types. Little is known about translational diﬀerences
between AC and SCC up to now.We hypothezise that eIF3a
and moreover its translational targets play a crucial role
in the distinction between pathogenic protein synthesis
regulation in SCC and AC. Currently, upregulation of eIF3a
isbelievedtonotinvolvethewholeeIF3complexsuggestinga
speciﬁc role of eIF3a in cancer development and progression
rangingpossiblybeyonditsprimeproteinsyntheticfunction.
It will be interesting to understand how eIF3a inﬂuences
downstream proteins, probably by targeted translation, and
thereby regulation of cell proliferation molecules, including
the already identiﬁed cell cycle regulator p27, tyrosinated
α-tubulin, and ribonucleotide reductase M2 subunit [11,
20, 21]. Recently, it was also reported that eIF3a modulates
nucleotide excision repair (NER) protein functions [22, 23].
It was shown that upon knockdown of eIF3a, the expression
of XPA, XPC, RPA32, and RAD23B is increased. eIF3a was
reported to inﬂuence response to cisplatin therapy, which
acts as a DNA-damaging agent via this pathway [22].
The aim of this study was to determine the diﬀerential
expression of the translation initiation factor eIF3a in tumor
tissues of OSCC. We hypothesized that upregulation of eIF3a
correlates with carcinogenesis, therefore, representing a
novelcancerbiomarker.Thestudycohortenableddescribing
the eﬀect of eIF3a upregulation in a subgroup receiving
chemotherapy, which is important knowledge to conﬁrm
correlative data of eIF3a expression and consequences for
NER, as have been published for other tumor entities [22,
23].
2.MaterialsandMethods
2.1. Patients. This retrospective study included 103 patients
who were operated with OSCC at the Department of
Maxillofacial Surgery, Innsbruck University Hospital in the
years between 1980 and 1997. From all of them, clinical
followup data are available. The tumor material was ﬁxed
in formalin and paraﬃn-embedded according to routine
methods. The study was conducted in accordance to the
regulations of the local ethics committee and Austrian law.
The cohort includes 79 (76.7%) male and 24 (23.3%)
female patients. Their range of age is 25–86 years, with a
medianof63years.Twenty-eight(27%)patientsweretreated
by radiotherapy, 88.9% of these patients suﬀered from a
high grade tumor. Twenty-eight (27%) patients received a
platinum-based chemotherapy. A haematoxylin and eosin
stainingwasperformedonallslidesofeachclinicalspecimen
and assessed independently by two experienced and board-
certiﬁed pathologists (J. Haybaeck, P. Obrist) in a blinded
manner, according to standard pathology criteria, for tumor
grading and staging. A summary of pathological features is
shown in Table 1.
2.2. TMA. The tissue microarray (TMA) paraﬃn blocks
were manufactured by a maxillofacial surgeon (k. Laimer)
and a pathologist (P. Obrist). Representative tumor areas
were identiﬁed on a haematoxylin-eosin-stained tumor slide
and in the following were punched out, at a diameter
of 2mm, of the original paraﬃn block. The collection of
punched tumor cones were united in a blank recipient paraf-
ﬁn block employing a precision instrument for assembly
(Manual Tissue Arrayer, MTA-1, Beecher Instruments, Sun
Prairie, Wis.). In this study, 4 diﬀerent TMA blocks were
used, containing approximately 30 tumor cones, according
to a speciﬁc pattern. The sections taken were 5μm thick,
mounted on speciﬁc adhesive-coated glass slides, compatible
for immunohistochemical staining and analysis.Journal of Oncology 3
Table 1: Distribution of conventional clinico-pathological param-
eters of patients with OSCC in relation to eIF3a expression.
eIF3a expression
Parameter Low (%) high (%)
Number of patients 34 66
Sex
Male 47 30
Female 19 4
Grading
I 24.2 14.7
II 57.6 52.9
III 18.2 32.4
pN
0 42.2 64.3
I 20.0 10.3
II 35.6 25.0
III 2.2 0
pT
I8 3
II 18 11
III 4 2
IV 17 10
2.3. Immunohistochemistry. The antibody used to determine
expressionofeIF3awasamonoclonalrabbitantibody(eIF3A
(D51F4) XP Rabbit mAb number 3411, Cell Signaling Tech-
nology, Danvers, MA). Staining was essentially performed as
previously described using the Dako Autostainer Universal
Staining System [24]. Endogenous peroxide blocking was
achieved with incubation of TMA slides in 3% hydrogen
peroxide for 5 minutes. The primary anti-eIF3a antibody
was applied at a dilution of 1:100, for 60 minutes,
followed by incubation with peroxidise-labelled secondary
antibody for 30 minutes and substrate-chromogen 3,3 -
diaminobenzidine tetrahydrochloride for 8 minutes. Coun-
terstaining was performed in aqueous haematoxylin for 45
seconds.
eIF3a expression was evaluated in terms of signal inten-
sity (intensity score) and density (proportion score). The
intensity score describes the staining intensity in comparison
to a control staining (0 no staining, 1 weak, 2 moderate, 3
high); proportion score represents the estimated fraction of
positively stained tumor cells (0–100%).
2.4. Statistical Methods. All calculations and the statistical
analyses were performed using the statistical software pro-
gram SPSS for Windows (SPSS, Inc. Chicago, IL). Diﬀer-
ences between groups were tested for statistical signiﬁcance
applying the χ2 test. Kaplan-Meier statistics were used to
describe and calculate survival curves. Patients who were
lost during followup were censored in the followup time
parameter. For this method, P-values were evaluated by the
log-rank test for censored survival data. The signiﬁcance of
eIF3a status for chemotherapy sensitivity and diﬀerence in
overall survival was additionaly calculated in a multivariate
ANOVA. Interparameter correlations were assessed accord-
ing to Spearman’s nonparametric test. For all analyses, a P-
value < 0.05 was deﬁned as statistically signiﬁcant.
3. Results
The expression of eIF3a in the analysed OSCC TMA was
evaluated by two pathologists (J. Haybaeck, P. Obrist). The
intracellular eIF3a localisation was predominantly perinu-
clear, as can be expected to be the translationally active eIF3a
in association to the endoplasmic reticulum. Even high-
grade tumors were not completely positive for eIF3a. A zonal
eIF3aexpressiondistributionpatternwasobservedincluding
regions with high, intermediate and low expression found
adjacent to each other (Figure 1).
For statistical analyses, staining proportion score (PS)
and intensity score (IS) were calculated reaching a total
immunostaining score (TIS). To do so, PS values were cat-
egorised in the following way: no cells positively stained = 0,
<20% = 1, 21–50% = 2, 51–80% = 3, >80% = 4. With
these values, TIS was obtained by multiplication of IS and
PS (TIS = IS × PS), resulting in TIS values ranging from
0 to 12, with only nine possible values (0, 1, 2, 3, 4, 6, 8,
9, 12). With this scoring system, statistics were calculated,
based on the cut oﬀ that TIS ≥ 4 represents samples with
an overexpression of eIF3a. In our cohort, 66% of samples
showed an overexpression of eIF3a (Table 1). In detail, 2.8%
had a score 0; 9.8% a score 1; 4.2% a score 2; 8.4% a score
3 and 4 each, the majority of 25.9% had an eIF3a score of 6
and 12.6% reached a score of 9.
The overall survival of patients in this study ranged from
1 to 245 months, with a median value of 27.2 months.
The inﬂuence of eIF3a expression on overall survival was
tested and blotted in a Kaplan Meyer curve (Figure 2)a f t e r
having performed log-rank statistics. A clear diﬀerence is
observedinpatientswithhighandloweIF3aexpression(P =
0.021), indicating that eIF3a overexpression is associated
with a better overall survival. The average overall survival of
patients baring eIF3a overexpressing tumors was 69 months
(5.8 years), compared to 36 months (3 years) in patients with
tumors of low eIF3a expression levels.
Our patient cohort is a representative set of OSCC
patients, veriﬁed by a typical pattern of overall survival
compared to tumor grade and stage (Figures 3(a) and 3(b)).
Opposingly, we could not show any signiﬁcant associ-
ation of eIF3a expression with clinical stage (P = 0.948),
tumor grade (P = 0.221), age (P = 0.452), sex (P =
0.055), and nodal status (P = 0.716). Expression of eIF3a
also showed no signiﬁcant diﬀerence in patients’ response
to radiotherapy (Figures 4(a) and 4(b)). The better overall
survival of patients with high eIF3a expression is evident
here, but not dependent on radiotherapy. As can be also
seen in Figure 4, patients receiving no radiotherapy have
a better overall survival, which is based on the fact that
patients undergoing radiotherapy were mainly suﬀering
from high grade tumors. This subgroup of patients receiving
radiotherapy comprised to 11.1% G1, 58.3% G2, and 30.6%
G3 tumors.4 Journal of Oncology
(a) (b) (c)
(d) (e) (f)
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Figure 1: Microscopic pictures of the expression patterns of eIF3a in OSCC (200x). (a): Normal squamous epithelium with only slight
inhomogeneous, mostly perinuclear eIF3a expression. (b): Low expression of eIF3a. (c/d) show a intermediate expression of eIF3a; (f–j)
represent a high expression pattern of eIF3a.
Further, a subgroup analysis was performed on patients
receiving chemotherapy (n = 28). 72% of chemothera-
peutically treated patients displayed an overexpression of
eIF3a (TIS ≥ 4). The representative subgroup comprises
25% grade 1 (n = 7), 39% grade 2 (n = 11), and
36% grade 3 (n = 10) tumors, of 20 male (71%) and 8
female (29%) patients. The overall survival was analysed
in those four groups and compared statistically by means
of a multivariate ANOVA, revealing a signiﬁcant diﬀerence
in overall survival in patients receiving platinum-based
chemotherapy, dependent on their eIF3a expression status
(P = 0.034). The average overall survival for patients with
high eIF3a levels was 67.2 and 53.3 years, with and without
chemotherapy, respectively, and 27.9 and 35.7 years for
patients with low eIF3a, with and without chemotherapy,
respectively (Table 2; Figure 5).Journal of Oncology 5
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Figure 2: Kaplan-Meyer curve. Association of eIF3a expression
with survival time in OSCC. The blue line indicates patients with
eIF3a TIS > 4, the green line represents eIF3a overexpressing
patients, with a TIS ≥ 4. The diﬀerence was signiﬁcant in a log-rank
test (P = 0.021).
4. Discussion
Squamous cell carcinoma of the oral cavity and oropharynx
is a major representative of head and neck cancer, which
accounts worldwide for approximately 4% of total carci-
n o m a si nm e na n d2 %i nw o m e n .T h e s er a t e sv a r yg e o -
graphically. Prognosis of OSCC is based on TNM classiﬁed
clinical staging and tumor grading [25]. In the past years,
diﬀerent strategies adding chemotherapy to radiotherapy
were developed in order to improve treatment outcome [26].
Nevertheless, especially the identiﬁcation of tumor markers
as prognostic as well as predictive factors allows an accurate
selection for assignation of patients to optimal therapy.
In this study, we show that eIF3a is overexpressed in
OSCC which correlates with a signiﬁcant better prognosis of
the patient. Analysing overall survival in patients receiving
radiotherapy, we could not show a signiﬁcant involvement
of eIF3a expression status in therapy response rates. On the
other hand, eIF3a overexpressing OSCC were identiﬁed to
better respond to platinum-based chemotherapy.
The multisubunit translation initiation factor eIF3 is
knowntobeorchestratedby13diﬀerentproteins.Allofthese
eIF3 proteins (eIF3a–eIF3m) are encoded on genetically
diﬀerent loci and were reported to assembly to diﬀerent eIF3
subcomplexes [27]. 27 such subcomplexes are known to date
and were characterized by mass spectrometry. eIF3a is part
of 3 such subcomplexes, suggesting a putative independent
mode of action [27]. This awareness to a special position
of eIF3a among translation initiation factors initiated many
studies investigating the role of eIF3a in a multitude
of pathways, interactions, and cancer entities where it is
intermingled.
In a mouse model, eIF3a expression was analysed in
various tissues and in the course of fetal and postnatal devel-
opment [28]. It was shown that eIF3a is highly expressed
in fetal compared to diﬀerentiated tissues. Strikingly, eIF3a
expression, which was reduced in all analysed postnatal
specimen, almost vanished in tissue samples of postnatal
lung, intestine, and stomach [28]. Similar ﬁndings show that
even in adult mice eIF3a expression in mucosal intestinal
cells which are diﬀerentiated is low or absent whereas
high expression patters are seen in basal intestinal cells of
healthy adult mice [28]. In vitro assays of colon cancer cell
lines indicated a similar dependence on decreased eIF3a
expression for diﬀerentiation of cells [28]. Still, a thorough
pathway and translational target analyses of how eIF3a is
regulating early development and cellular diﬀerentiation is
still lacking and should be expected with great interested
from future studies.
This association of eIF3a with early development is
paralleled with ﬁndings of an upregulation in cancer. In
vitro studies, conducted in immortalized ﬁbroblast cells,
showed that the overexpression of eIF3a led to a malignant
transformation of these cells [29]. This transformation
manifestedintheformationoftransformedfoci,suppression
of apoptosis, and an increased in the measured polysomes
to monosomes ratio [29]. These in vitro ﬁndings suggest
thatespeciallythepatternofspeciﬁctranslationallyregulated
proteins determines the transforming potential of immor-
talized ﬁbroblasts and that eIF3a is recruiting a proteome
capable of such malignant transformation. In vivo, eIF3a is
found overexpressed in a range of tumor entities, where it
was described in association with a rather contrastive clinical
outcome. On the one hand, based on in vitro experiments in
lung and breast cancer cell lines, eIF3a was suggested to be
involved in the development of cancer and to be aﬃliated
to sustained malignancy [13]. An association of eIF3a
overexpression with poor clinical prognosis was reported
recently in colon cancer patients following surgery [19]. This
coherence and proclamation of eIF3a as procancer molecule
is in line with the ﬁndings by Liu et al. on early mouse
embryonicdevelopmentandfurtherbasedonthetheorythat
eIF3a is regulating the translation of a speciﬁc, development-
and diﬀerentiation-, as well as cancer-associated subset of
mRNAs rather than global translation initiation. Known
translational targets of eIF3a are the cell cycle regulators
p27, tyrosinated α-tubulin, and ribonucleotide reductase M2
subunit, a key regulator of DNA synthesis [13]. On the
other hand, studies in squamous cell carcinoma of the cervix
and esophagus showed eIF3a expression to correlate with
better prognosis. eIF3a expression was discussed to protect
cells from progression into higher malignancy and to reduce
metastatic potential of the respective tumors [16]. These
ﬁndings underline that eIF3a is a key molecule of cancer
development and progression, though not readily deﬁned
to date. Our ﬁnding that eIF3a upregulation interrelated
to better overall survival in OSCC patients agrees with
previous ﬁndings in other SCC. The diverse ﬁndings on6 Journal of Oncology
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Figure 3: (a): Overall survival of patients with diﬀerent tumor grading, (b): overall survival of patients with diﬀerent tumor stage.
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Figure 4: (a): Overall survival of patients with high and low eIF3a expression receiving no radiotherapy, (b): overall survival of patients with
high and low eIF3a expression receiving radiotherapy.Journal of Oncology 7
Table 2: Overall survival in months of patients receiving platinum-
based chemotherapy (1) or not (0), with respect to their eIF3a
expression status.
eIF3a expression
Low High
Platinum-based
chemotherapy
Average overall survival (months)
1 67.2 27.9
0 53.3 35.7
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Figure 5: Kaplan-Meyer curve. Overall survival of patients receiv-
ing platinum based-chemotherapy. The red line represents patients
with high eIF3a expression, the green line represents patients with
low eIF3a expression (P = 0.037).
eIF3a expression and associated clinical parameters are
hypothesised to be highly dependent on tumor origin. Little
is known about the diﬀerences of protein synthesis in AC
versus SCC but our data corroborate a contrasting pattern
andmodalityoftranslation(initiation)inwhicheIF3aseems
to play a central role.
The regulation of tyrosinated α-tubulin could link eIF3a
expression to tumor therapy via the chemotherapeutic
Docetaxel. Docetaxel is a tumor-therapeutic agent acting
on the formation of microtubule and prevents physiological
disassembly of microtubules, as required in mitotic cell
division [11, 30]. A possible correlation of eIF3a expression
and response to Docetaxel therapy should be analysed in
followup studies. Preliminary, suggestive data is available,
as it was recently shown the treatment of A549 lung cancer
cells with docetaxel upregulates eIF3a expression in vitro
[31]. Recently, a new group of eIF3a downstream targets that
might have huge impact on tumor therapy decisions and
introduce eIF3a as not only prognostic but also a predictive
tumor marker that was discovered in the NER pathway. It
is well known that tumor formation is often associated with
impaired capability of DNA damage repair or cell cycle upon
recognition of (spontaneous) mutations. Pathways required
for these control mechanisms are drug-able in recent times,
meaning that they may be targeted by chemotherapeutics. As
example, platinum-based chemotherapeutics, like cisplatin
or carboplatin, induce DNA double-strand breaks that need
to be repaired by the complex process of NER. Main
contributors to this pathway are xeroderma pigmentosum
complementation group proteins (XPA, XPC), radiation-
sensitive mutant 23 homolog B (RAD23B), as well as repli-
cation protein A (RPA). These were analysed for their eIF3a
dependence in an in vitro model systems for nasopharyngeal
carcinoma [22]. eIF3a was shown to negatively regulate
the NER proteins and, therefore, to reduce DNA repair in
cancer cells, which leads to increased apoptosis compared
to cells with reduced eIF3a. Thus, elevated levels of eIF3a
seem to hinder NER and thereby mutation incorporation
and furthermore sensitizes cells to the treatment of DNA
damaging agents [22]. These ﬁndings were veriﬁed in a
patient cohort receiving platinum-based chemotherapy as
ﬁrst-line therapy against primary lung tumors, where tumor
patients with high eIF3a expression responded signiﬁcantly
better to platinum-based chemotherapy [23]. In the present
study, we found that eIF3a was highly expressed in respon-
ders in comparison to nonresponders of OSCC patients
platinum-based chemotherapy. Here, it should be noted
that, being assigned according to today’s standard selection
criteria, patients receiving cisplatin or carboplatin survived
in average 53 months after diagnosis compared to 47 month
in patients who did not undergo this treatment. This
promotes the ongoing extensive investigation into discovery
of novel biomarkers for suitability as molecular indicators
of therapy response in OSCC patients. eIF3a was shown to
be a potent biomarker fulﬁlling the stated requirement, as
we found a signiﬁcant correlation of eIF3a expression with
better treatment response and increased overall survival. It
is important to stress that in our ﬁndings, without eIF3a
overexpression, a platinum-based therapy regimen would
rather present a contraindication. Patients with low eIF3a
expressing OSCC receiving platinum-based neo-djuvant
therapy had a decreased overall survival of an average
8 months. Future fortiﬁcation of these data is required
by analysis of a bigger study cohort undergoing therapy.
Platinum-based chemotherapeutics may be the ﬁrst ones
with a described dependence on a translational regulator
as eIF3a. Nevertheless, the number of treatment strategies
considering translation (initiation) as putative target is enor-
mously increasing [32–34]. Rapamycin and novel analogue
molecules, so-called Rapalogs, represent one class of putative
tumor therapeutics which act by inhibiting protein synthesis
via the mammalian target of rapamycin, mTOR. The kinase
protein mTOR is activating protein synthesis by phospho-
rylation of downstream S6 kinase and 4E-binding proteins,
which will in turn release eIF4E and trigger canonical
translation initiation. Among eIFs, especially eIF4 and its
subunits, represent interesting new targets for inhibition of8 Journal of Oncology
translation initiation in tumor therapy [35–37]. eIF3 should
not be neglected in this context, as the various compositions
of the multisubunit complex, targeting diﬀerent subsets of
mRNAs for translation, represent target entities which might
enable a more speciﬁc inhibition of tumor-related gene
expression.
5. Conclusion
The investigation of predictive biomarkers helps diﬀer-
entiating likely responding patients from nonresponders.
eIF3a was suggested to be a prognostic factor in OSCC
with a high expression being associated with better clinical
outcome. eIF3a might be a potent candidate as predictive
tumor marker for evaluating sensitivity to platinum-based
chemotherapy. To further validate eIF3a as a potential
predictive and prognostic marker, future adjuvant trials
using chemotherapy in addition to radiation therapy in
oral squamous cell carcinoma should consider incorporating
eIF3a in their correlative studies. Considering the many
cancer entities where eIF3a is already described, this leaves
eIF3a as a putative broad-range tumor marker which might
still bear important keys for unlocking present issues in
cancer diagnostics and therapy.
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